Bacillus Calmette-Guérin immunotherapy for genitourinary cancer.
about
Immunobiology and immunotherapy in genitourinary malignanciesFrom kinetics and cellular cooperations to cancer immunotherapiesApplications of bacillus Calmette-Guerin and recombinant bacillus Calmette-Guerin in vaccine development and tumor immunotherapyMycobacteria emulsified in olive oil-in-water trigger a robust immune response in bladder cancer treatment.Mistletoe lectin has a shiga toxin-like structure and should be combined with other Toll-like receptor ligands in cancer therapy.Effects of programmed death-ligand 1 expression on OK-432 immunotherapy following transurethral resection in non-muscle invasive bladder cancerMucosal SIV Vaccines Comprising Inactivated Virus Particles and Bacterial Adjuvants Induce CD8(+) T-Regulatory Cells that Suppress SIV-Positive CD4(+) T-Cell Activation and Prevent SIV Infection in the Macaque Model.Immunotherapy for bladder cancer.Chromosomal alterations in exfoliated urothelial cells from bladder cancer cases and healthy men: a prospective screening studyNKG2D is a Key Receptor for Recognition of Bladder Cancer Cells by IL-2-Activated NK Cells and BCG Promotes NK Cell ActivationMincle, an Innate Immune Receptor, Is Expressed in Urothelial Cancer Cells of Papillomavirus-Associated Urothelial Tumors of Cattle.Neonatal Bacillus Calmette-Guérin vaccination alleviates lipopolysaccharide-induced neurobehavioral impairments and neuroinflammation in adult mice.Recurrence and progression in nonmuscle invasive transitional cell carcinoma of urinary bladder treated with intravesical Bacillus Calmette-Guerin: A single center experience and analysis of prognostic factors.BCG immunotherapy for bladder cancer--the effects of substrain differences.Cytokines as effectors and predictors of responses in the treatment of bladder cancer by bacillus Calmette-Guérin.Recombinant Mycobacterium bovis BCG for immunotherapy in nonmuscle invasive bladder cancer.The immunotherapy of canine osteosarcoma: a historical and systematic review.New Strategies in Bladder Cancer: A Second Coming for Immunotherapy.Characterization of a human anti-tumoral NK cell population expanded after BCG treatment of leukocytes.Reduced estimated glomerular filtration rate (eGFR <60 mL/min/1.73 m2 ) at first transurethral resection of bladder tumour is a significant predictor of subsequent recurrence and progression.Systemic therapy in muscle-invasive and metastatic bladder cancer: current trends and future promises.5-Aminolevulinic acid-mediated photodynamic therapy for bladder cancer.Intravesical bacillus Calmette-Guérin versus chemohyperthermia for high-risk non-muscle-invasive bladder cancer.Impact of 2004 ISUP/WHO classification on bladder cancer grading.Fluorescence in situ hybridization as prognostic predictor of tumor recurrence during treatment with Bacillus Calmette-Guérin therapy for intermediate- and high-risk non-muscle-invasive bladder cancer.Systemic BCG-osis following intravesical BCG instillation for bladder carcinoma.Intravesical Gemcitabine versus Intravesical Bacillus Calmette-Guérin for the Treatment of Non-Muscle Invasive Bladder Cancer: An Evaluation of Efficacy and Toxicity.Expert consensus document: Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer.Intratumoral immunotherapy: using the tumor as the remedy.Anti-tumor immunity via the superoxide-eosinophil axis induced by a lipophilic component of Mycobacterium lipomannan.A Festschrift in Honor of Edward M. Messing, MD, FACSThe role of fluorescence in situ hybridization to predict patient response to intravesical Bacillus Calmette-Guérin therapy for bladder cancer: A diagnostic meta-analysis and systematic reviewHeterologous effects of infant BCG vaccination: potential mechanisms of immunity
P2860
Q26738668-0001166E-B339-4D95-8891-7AFC680196F4Q26750783-0A4E7C6E-C216-4F1E-BC73-24E6C53AB5CEQ26798372-D1A7A7D6-F7EA-4861-AEBD-DFF3C79AC63FQ27346705-D11E7360-3B80-4AA0-A2CC-9E8E9B11E747Q30351915-2D815637-6DCC-460C-824E-C60DE74A0465Q33751253-9F4EB229-AE46-4328-B317-BD0959CA853DQ33820903-4DA443AD-340A-4C2B-BD0A-C5EA487B48C3Q34477444-5CDB4192-DB8C-40C9-A5F8-AD14279C18B9Q34587111-FC87A177-CB0A-4AC7-90C8-4C734B1BD5FCQ35693194-DDCD2076-64F7-48E6-9814-534FEAF7E1E7Q35826351-3E06FB8D-9F58-4EEE-9886-372972C71514Q37082976-EE338E11-8FD3-4CFC-A903-E33FB68C7FFBQ37094285-F304B779-EE42-4FB7-9A06-970938C64F23Q38138412-22B579F0-05E9-45B2-A524-7F1B9CFE8235Q38232854-66E7B692-FCB1-4432-96C7-F91DC109AA02Q38385719-FB08B6A6-8DC2-4861-AD36-1D208611BB03Q38451770-20A18B84-9F0A-4ED9-9902-0DB2619DB1E6Q38673585-A7156C73-7256-475A-B54B-906D74BB4CE1Q38784439-055C079B-0561-410F-808C-32F5CD8A1176Q38808544-65BBB26B-B149-4039-B27D-FA3935F948C3Q38852690-A9CA5076-3629-4971-A5B2-8377E550F3C6Q39133125-52065DE4-5D9C-4BF7-B59F-10616D5F5441Q40899426-C23B7EE0-6319-4C1A-99F8-D112F549717AQ41125821-DBC8296D-8031-4E39-A22C-C70EEC5C8069Q41597185-3FA9D66F-4CE6-4A67-B3B9-AAC2BD19EA10Q42279503-DC804D1E-1ECE-478C-A5CE-CCD564DDC237Q46075170-730CC566-99D2-478F-BE5B-890C1D6D8E95Q46851166-725D152D-4256-4BF3-AEE8-17206918B12DQ47281370-6B101F8E-B358-419C-AA95-BAC114C5A17AQ50551982-5D4760EC-BAB8-4FDE-A543-0F3FB9505A5FQ58691149-E5C8F7F5-7E95-4AA3-98D0-109DD89A7F85Q58759162-7E490765-6595-498B-AD8F-B08974BCC287Q58767332-530D9C4E-8632-43B5-9F21-C2DE14E3B1FE
P2860
Bacillus Calmette-Guérin immunotherapy for genitourinary cancer.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Bacillus Calmette-Guérin immunotherapy for genitourinary cancer.
@en
type
label
Bacillus Calmette-Guérin immunotherapy for genitourinary cancer.
@en
prefLabel
Bacillus Calmette-Guérin immunotherapy for genitourinary cancer.
@en
P2093
P2860
P1433
P1476
Bacillus Calmette-Guérin immunotherapy for genitourinary cancer.
@en
P2093
Alvaro Morales
Donald L Lamm
Nilay M Gandhi
P2860
P304
P356
10.1111/J.1464-410X.2012.11754.X
P577
2013-03-20T00:00:00Z